



**Report of the 1st NRL proficiency testing on
“Detection of anti-*Toxoplasma* IgG in ovine serum
samples”**

March - April, 2015

Table of contents

| | | |
|----|---|----|
| 1 | Introduction | 3 |
| 2 | Scope | 3 |
| 3 | Time frame | 3 |
| 4 | Test material | 3 |
| 5 | Instructions to participants | 3 |
| 6 | Criteria for the result evaluation and statistical analysis | 4 |
| 7 | Participating laboratories | 4 |
| 8 | Results | 4 |
| | 8.1 Delivery of package to NRLs | 4 |
| | 8.2 Test methods | 4 |
| | 8.3 Evaluation | 5 |
| 9 | Conclusions | 5 |
| 10 | References | 5 |
| | Annex 1 | 6 |
| | Annex 2 | 7 |
| | Annex 3 | 8 |
| | Annex 4 | 9 |
| | Annex 5 | 10 |
| | Annex 6 | 11 |
| | Annex 7 | 12 |

1 Introduction

The obligate intracellular parasite *Toxoplasma gondii* is a protozoan of the Phylum Apicomplexa highly prevalent in humans and animals worldwide. Its clinical relevance is mainly due to potential congenital transmission to the foetus by seronegative women, causing intrauterine death or severe sequelae in the newborn and adult life. The major role in disease transmission is played by the oral ingestion of either bradyzoites encysted in the tissues of chronically infected warm blooded animals or sporozoites contained in the highly resistant environmental stage oocyst (Dubey, 2009). Sheep, along with goats and pigs, are the animal species mostly associated with human infections (Esteban-Redondo et al., 1999, Jones et al., 2009). Consequently, field studies on the seroprevalence of *T. gondii* are needed to estimate the risk for humans.

2 Scope

The proficiency testing (PT) aims to evaluate the competence of the appointed NRLs to detect anti-*Toxoplasma* IgG in ovine serum samples. The organization of PTs falls in the duties of the EURL for Parasites, as it is stated in the Regulation (EC) No 882/2004 of the European Parliament and of the Council (Commission Regulation No. 882/2004). The 1st PT on detection of anti-*Toxoplasma* IgG in ovine serum samples was organized following the request of NRLs during the 2014 EURLP annual workshop.

3 Time frame

The PT was first announced to NRLs by email on January 15th, 2015. A second email was sent to all NRLs on February 6th, 2015, including the participation forms (see Annex 1; MO/MAQPVI/01.PT Request Form) and the deadline to send it back. On March 16th, 2015, the samples were dispatched to participants by an international courier.

4 Test material

The test material forwarded to each laboratory consisted of a panel of 10 serum samples (Annex 2). Serum samples were collected from *T. gondii* naturally infected and uninfected sheep. All serum samples were individually tested for anti-*Toxoplasma* IgG by a commercial kit (ID Screen® Toxoplasmosis Indirect Multi-species Indirect ELISA TOXOS-MS). Serum samples were pooled according with their potency, optical density (OD) value, preserved with 1% merthiolate solution, and then tested again to confirm their positivity/negativity. Samples were further distributed in 250 µL aliquots, labelled with a code, and then put in a plastic bag sealed under vacuum, identified by an alphanumeric code stuck on the plastic bag and stored at +4 °C. Samples were forwarded to each participant laboratory by an international courier in a polystyrene box with cooler packages to maintain a temperature lower than +15 °C during shipping. Packages were forwarded according to the international forwarding regulations.

The stability of the samples was evaluated by testing twice, before and 10 days after the forwarding, the panel of serum samples. Differences between the two OD determinations were lower than 0.5 units (Annex 3).

To detect anti-*Toxoplasma* IgG in serum samples, any serological test based on the detection of anti-*Toxoplasma* IgG could be used. Each laboratory had to use the test/s routinely used.

5 Instructions to participants

From February 6th, 2015, general information on the PT aim, instructions and procedures were made available to NRLs on the EURLP web site (<http://www.iss.it/crlp/index.php?lang=2&anno=2015&tipo=28>).

Electronic copies of the forms, which had to be filled in and sent back to EURLP, were sent by e-mail on March 16th, 2015, (see Annex 1; MO/POPVI/00 from 01.06 to 04.06):

- 1) "Check package", to inform about the content and the condition of the PT material at the arrival in the lab;
- 2) "Instruments and Materials List" to be reported if instruments and/or materials different from those present in the original kit were used;
- 3) "Procedure", to inform about the kit used and its expiration date. Any variation from the used method had to be reported;
- 4) "Result", to report the positivity or negativity of each sample.

The code assigned to the laboratory was sent individually to each participant laboratory by a separate e-mail on March 16th 2015.

6 Criteria for result evaluation and statistical analysis

The participating laboratory had to indicate the positivity or negativity of the tested samples. Evaluation of the results is qualitative for each serum sample, and it is reported as "correctly classified" or "incorrectly classified", irrespective of the IgG level found in the sample/s. Final evaluation is considered as "positive" if all samples are correctly classified and "negative" in all the other cases.

Due to the low number of samples in the panel, no statistical analysis of the results was performed. In April 2015, the EURLP sent an Individual PT Report (see Annex 4) to each participant laboratory as a pdf file by email.

7 Participating laboratories

Sixteen NRLs, coded from B to Q, participated in the PT (Annex 5).

8 Results

8.1 Package delivery to NRLs

All packages but two were delivered to participant laboratories within 24-72 hours (24 hours for 11 labs, 48 hours for 2 labs, 72 hours for one lab), one package was delivered after 7 days and one delivery date was not reported. At delivery, the internal temperature of the packages was ≤ 13 °C in 15 (94%) parcels; no information was provided from one NRL. The time elapsed from package delivery at the NRL and its control was ≤ 1 h for 14 laboratories, approximately 13 h for 1 laboratory, and it was not reported by one laboratory.

8.2 Test methods

Fourteen laboratories tested the serum samples by one method, and two laboratories used two methods (see Annex 6). The methods used by the participants were:

- Indirect Immunofluorescent assay
 - "in house" by laboratories B, K and O
 - Toxo-spot IF from Biomerieux by laboratories C and N;
- Enzyme Linked Immunosorbent Assay
 - LSIVET™ ruminant toxoplasmosis serum ELISA kit by laboratory O;
 - ID SCREEN® toxoplasmosis indirect multi-specie by laboratories F, G, J, L, P, Q;
 - IDEXX TOXOTEST Ab by laboratories D and H;
- Latex agglutination
 - "in house" by laboratory I;
 - Toxo-screen from Biomerieux by laboratories C, E and M.

8.3 Evaluation

All participant NRLs sent the results. All NRLs but one, correctly classified (as positive or negative) all serum samples (see Annex 7).

9 Conclusions

All laboratories but one (laboratory '1') correctly classified all serum samples. All methods used but the "in house agglutination test" used by laboratory '1', showed a 100% agreement with the expected results. The more frequently used commercial kits were immune-enzymatic assays, and among them, the ID SCREEN® toxoplasmosis indirect multi-species.

10 References

Dubey JP, 2009. Toxoplasmosis of animals and humans. CRC Press, 313 pp.

Esteban-Redondo I, Maley SW, Thomson K, Nicoll S, Wright S, Buxton D, Innes EA, 1999. Detection of *Toxoplasma gondii* in tissues of sheep and cattle following oral infection. *Vet Parasitol* 86, 155-171..

Jones JL, Dargelas V, Roberts J, Press C, Remington JS, Montoya JG, 2009. Risk factors for *Toxoplasma gondii* infection in the United States. *Clin Infect Dis* 49, 878-884.

Annex 2


Optical Density values at 450 nm and expected results of the serum sample panel

| Serum sample | Mean OD of duplicates | Expected results |
|--------------|-----------------------|------------------|
| 1 | 2.490 | positive |
| 2 | 2.622 | positive |
| 3 | 0.086 | negative |
| 4 | 2.040 | positive |
| 5 | 0.079 | negative |
| 6 | 1.545 | positive |
| 7 | 1.805 | positive |
| 8 | 0.085 | negative |
| 9 | 0.086 | negative |
| 10 | 2.197 | positive |

Annex 3

Serum samples stability

| Sample | First test (Mean OD of duplicates) | Second test (Mean OD of duplicates) |
|--------|--|---|
| 1 | 2.475 | 2.490 |
| 2 | 2.650 | 2.622 |
| 3 | 0.090 | 0.086 |
| 4 | 2.271 | 2.040 |
| 5 | 0.080 | 0.079 |
| 6 | 1.997 | 1.545 |
| 7 | 1.979 | 1.805 |
| 8 | 0.085 | 0.085 |
| 9 | 0.086 | 0.086 |
| 10 | 2.225 | 2.197 |



Scatter plot of the differences between the optical density (OD) of two determinations of each pooled of serum samples. OD was recorded at 450 nm.

Annex 4

Report form

European Union Reference Laboratory for Parasites
 Department of Infectious, Parasitic and Immunomediated Diseases
 Unit of Gastroenteric and Tissue Parasitic Diseases
 Istituto Superiore di Sanità

Individual-PT-Report-n.15/0XX → → → → → → → → → → Laboratory-Code: _._. _

PT-"Detection of anti-Toxoplasma-IgG in ovine serum samples"

Name

Institution

Address

Tel Fax e-mail

Criteria for the result evaluation

The PT result evaluation is expressed as "correctly classified" (right identification of positives and negatives) or "incorrectly classified" (false positive or false negative).

The final evaluation is "positive" if the results of all samples are correct. The final evaluation is "negative" if at least one result is incorrect.

| SAMPLE CODE | Results | Expected results | Evaluation |
|-------------|--------------------------|--------------------------|--------------------------|
| Tx1 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx2 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx3 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx4 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx5 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx6 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx7 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx8 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx9 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Tx10 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

NOTE:

FINAL EVALUATION: POSITIVE

Date → → → → → → → → → → Head of EURL
 Dr. Edoardo Pozio

CONFIDENTIALITY: the report is sent, in the pdf format, by e-mail to the participant laboratory only. The EURLP reserves itself the right to provide, on request, the present PT result to the competent authority.

End of the report

PT-Provider → → → → → → → → → → PT-Coordinator
 Unit of Gastro-enteric and Tissue Parasitic Diseases → → → → Dr. Gomez Morales-Mate Angeles
 Istituto Superiore di Sanità, Rome, Italy → → → → e-mail: parasitologia@iss.it; tel: +39 06 4990 20798
 Viale Regina Elena, 289 - 00161 Rome, Italy

MGMAGP/1/05.05 rev. 05 page 1 of 15

Annex 5

Participant National Reference Laboratories

| Participant institutions | Country |
|--|-------------|
| Scientific Institute of Public Health (WIV-ISP), Brussels | Belgium |
| Estonian Veterinary and Food Laboratory, Tartu | Estonia |
| Finnish Food Safety Authority, Evira, Oulu | Finland |
| Laboratory for Animal Health, ANSES, Maisons-Alfort | France |
| Laboratorio Central de Sanidad Animal, Santa Fe, Granada | Spain |
| Friedrich-Loeffler Institute, Federal Research Institute for Animal Health, Wusterhausen | Germany |
| Center of Athens Veterinary Institutions, Department of Parasitology, Athens | Greece |
| Institute of food safety, animal health and environment, Riga | Latvia |
| National Food and Veterinary Risk Assessment Institute, Vilnius | Lithuania |
| Faculty of Veterinary Medicine, Skopje | Macedonia |
| National Institute of Public Health and the Environment, RIVM, Bilthoven | Netherlands |
| National Veterinary Research Institute, Pulawy | Poland |
| National Laboratory of Veterinary Research, Lisboa | Portugal |
| Institute for Diagnosis and Animal Health, Bucharest | Romania |
| Institute for Medical Research, University of Belgrade, Belgrade | Serbia |
| Veterinary Faculty, University of Ljubljana, Ljubljana | Slovenia |
| Institute of Parasitology, University of Bern, Bern | Switzerland |

Annex 6

Serological methods used by the participant laboratories

| Method | In house/commercial kit | NRL code |
|---------------------|--------------------------------|------------------|
| IFA | in house | B, K, O |
| | Toxo-spot, Biomerieux | C, N |
| ELISA | LSIVET™ ruminant toxoplasmosis | O |
| | ID SCREEN® toxoplasmosis | F, G, J, L, P, Q |
| | IDEXX TOXOTEST Ab | D, H |
| Latex agglutination | in house | I |
| | Toxo-screen IF, Biomerieux | C, E, M |

Annex 7

Proficiency testing results

| Sample code | Expected results | NRL codes | | | | | | | | | | | | | | | |
|-------------|------------------|-----------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q |
| Tx1 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Tx2 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Tx3 | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - |
| Tx4 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Tx5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Tx6 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Tx7 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Tx8 | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - |
| Tx9 | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - |
| Tx10 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |